Lampiran 1 Lembar *JBI Critical Appraisal RCT Study*

LEMBAR *JBI CRITICAL APPRAISAL*
RANDOMIZED CONTROLLED TRIALS

THE JOANNA BRIGGS INSTITUTE

JBI Critical Appraisal Checklist for Randomized Controlled Trials

Reviewer_____Date_____

Author _____Year_____Record Number_____

		Yes	No	Unclear	NA
1.	Was true randomization used for assignment of participants to treatment groups?	☐	☐	☐	☐
2.	Was allocation to treatment groups concealed?	☐	☐	☐	☐
3.	Were treatment groups similar at the baseline?	☐	☐	☐	☐
4.	Were participants blind to treatment assignment?	☐	☐	☐	☐
5.	Were those delivering treatment blind to treatment assignment?	☐	☐	☐	☐
6.	Were outcomes assessors blind to treatment assignment?	☐	☐	☐	☐
7.	Were treatment groups treated identically other than the intervention of interest?	☐	☐	☐	☐
8.	Was follow up complete and if not, were differences between groups in terms of their follow up adequately described and analyzed?	☐	☐	☐	☐
9.	Were participants analyzed in the groups to which they were randomized?	☐	☐	☐	☐
10.	Were outcomes measured in the same way for treatment groups?	☐	☐	☐	☐
11.	Were outcomes measured in a reliable way?	☐	☐	☐	☐
12.	Was appropriate statistical analysis used?	☐	☐	☐	☐
13.	Was the trial design appropriate, and any deviations from the standard RCT design (individual randomization, parallel groups) accounted for in the conduct and analysis of the trial?	☐	☐	☐	☐

Overall appraisal: Include ☐   Exclude ☐   Seek further info ☐

Comments (Including reason for exclusion)

_____

_____

_____

Lampiran 2 Lembar *JBI Case Study*

LEMBAR *JBI CRITICAL APPRAISAL CASE REPORTS*

THE JOANNA BRIGGS INSTITUTE

JBI Critical Appraisal Checklist for Case Reports

Reviewer_____Date_____

Author _____Year_____Record Number_____.

	Yes	No	Unclear	Not applicable
1. Were patient's demographic characteristics clearly described?	☐	☐	☐	☐
2. Was the patient's history clearly described and presented as a timeline?	☐	☐	☐	☐
3. Was the current clinical condition of the patient on presentation clearly described?	☐	☐	☐	☐
4. Were diagnostic tests or assessment methods and the results clearly described?	☐	☐	☐	☐
5. Was the intervention(s) or treatment procedure(s) clearly described?	☐	☐	☐	☐
6. Was the post-intervention clinical condition clearly described?	☐	☐	☐	☐
7. Were adverse events (harms) or unanticipated events identified and described?	☐	☐	☐	☐
8. Does the case report provide takeaway lessons?	☐	☐	☐	☐

Overall appraisal: Include ☐   Exclude ☐   Seek further info ☐

Lampiran 3 Kerangka Penyusunan Modul

Kerangka Penyusunan Modul

HALAMAN JUDUL

KATA PENGANTAR

DAFTAR ISI

DESKRIPSI MODUL

PENDAHULUAN

1. Materi
2. Tujuan
3. Petunjuk Penggunaan Modul
4. Panduan Implementasi Modul

BAB 1 KONSEP DIABETES MELLITUS

1.1 Deskripsi Singkat

1.2 Tujuan

1.3 Manfaat

1.4 Sasaran

1.5 Uraian Materi

1.6 Rangkuman

1.7 Evaluasi

1.8 Daftar Pustaka

BAB 2 MATERI INTERVENSI EDUKASI TEKNOLOGI BERBASIS *GAME* ANDROID

2.1 Deskripsi Singkat

2.2 Tujuan

2.3 Manfaat

2.4 Sasaran

2.5 Uraian Materi

2.6 Rangkuman

2.7 Evaluasi

2.8 Daftar Pustaka

BAB 3 MATERI INTERVENSI PSIKO-EDUKASI BERBASIS ANDROID

3.1 Deskripsi Singkat

3.2 Tujuan

3.3 Manfaat

3.4 Sasaran

3.5 Uraian Materi

3.6 Rangkuman

3.7 Evaluasi

3.8 Daftar Pustaka

BAB 4 MATERI INTERVENSI BERBASIS ANDROID DENGAN SMART DEVICE CONNECTION

4.1 Deskripsi Singkat

4.2 Tujuan

4.3 Manfaat

4.4 Sasaran

4.5 Uraian Materi

4.6 Rangkuman

4.7 Evaluasi

4.8 Daftar Pustaka

Lampiran 4 Lembar *PRISMA Checklist*

LEMBAR *PRISMA CHECKLIST*

Section/topic	#	Checklist item	Reported on page #
TITLE			
Title	1	Identify the report as a systematic review, meta-analysis, or both.	
ABSTRACT			
Structured summary	2	Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.	
INTRODUCTION			
Rationale	3	Describe the rationale for the review in the context of what is already known.	
Objectives	4	Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).	
METHODS			
Protocol and registration	5	Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.	
Eligibility criteria	6	Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.	
Information sources	7	Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.	
Search	8	Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.	
Study selection	9	State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).	
Data collection process	10	Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.	
Data items	11	List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.	
Risk of bias in individual studies	12	Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.	
Summary measures	13	State the principal summary measures (e.g., risk ratio, difference in means).	
Synthesis of results	14	Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I^2) for each meta-analysis.	

Section/topic	#	Checklist item	Reported on page #
Risk of bias across studies	15	Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).	
Additional analyses	16	Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.	
RESULTS			
Study selection	17	Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.	
Study characteristics	18	For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.	
Risk of bias within studies	19	Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).	
Results of individual studies	20	For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.	
Synthesis of results	21	Present results of each meta-analysis done, including confidence intervals and measures of consistency.	
Risk of bias across studies	22	Present results of any assessment of risk of bias across studies (see Item 15).	
Additional analysis	23	Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).	
DISCUSSION			
Summary of evidence	24	Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).	
Limitations	25	Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).	
Conclusions	26	Provide a general interpretation of the results in the context of other evidence, and implications for future research.	
FUNDING			
Funding	27	Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.	